[CAS NO. 926927-61-9] Motolimod (VTX-2337)
Please click "REQUEST A QUOTE" button if you need other sizes or custom synthesis
request a quote
If there is no stock, or you need other sizes or custom synthesis, please:
PRODUCTS SPECIFICATIONS [926927-61-9]
Store
Catalog
SLK-S7161
Brand
Selleck
CAS
926927-61-9
DESCRIPTION [926927-61-9]
Overview
| MDL | MFCD28044318 |
|---|---|
| Molecular Weight | 458.6 |
| Molecular Formula | C28H34N4O2 |
| SMILES | O=C(C1=CC2=CC=C(C3=CC=C(C(N4CCCC4)=O)C=C3)C=C2N=C(N)C1)N(CCC)CCC |
For research use only.
Storage
3 years,-20°C,powder
1 years,-80°C,in solvent
1 years,-80°C,in solvent
Shipping
Room temperature shipping(Stability testing shows this product can be shipped without any cooling measures.)
Preparing Stock Solutions
| 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.1805 mL | 10.9027 mL | 21.8055 mL |
| 5 mM | 0.4361 mL | 2.1805 mL | 4.3611 mL |
| 10 mM | 0.2181 mL | 1.0903 mL | 2.1805 mL |
| 50 mM | 0.0436 mL | 0.2181 mL | 0.4361 mL |
Description
Motolimod (VTX-2337) is a selective and potent agonist with of 100 nM, > 50-fold selectivity over TLR7. Phase 2.
Targets
| TLR8 [1] |
| 100 nM(EC50) |
In vitro
VTX-2337 stimulates the production of both TNFα with EC50 of 140 nM and IL-12 with EC50 of 120 nM in PBMCs. In monocytes and mDCs, VTX-2337 selectively induces the production of TNFα and IL-12 via NF-κB activation. VTX-2337 also stimulates IFNγ production from NK cells, augments the lytic function of NK cells and enhances ADCC.
In vivo
In an ovarian cancer mouse model, TX-2337 enhances the effect of pegylated liposomal doxorubicin (PLD).
References
Powered by Arctom Copyright © 2026 Arctom. All rights
reserved.